US Pharma MarketingNearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.
Q32 bounces back to claim study success for alopecia drug
Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.
Source: BioPharma Dive